Intra-articular Injection: A Innovational Approach for Joint Disorder
Impact of Intra-articular Injection on Temporomandibular Joint Disorder
1 other identifier
interventional
88
0 countries
N/A
Brief Summary
The goal of this clinical trial is to study about the clinical effect of Intra-articular Injection on Temporomandibular Joint Dysfunction The main question it aims to answer is: • Can Intra-articular Injection help improve the Temporomandibular Joint Dysfunction Participants will be randomly assigned into the experimental group and the control group, all under comprehensive treatment. The experimental group will be given Intra-articular Injection additionally, The study lasts 15 days for each patient. Researchers will compare the assessments between the two groups to see if Intra-articular Injection can help improve the Temporomandibular Joint Dysfunction
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2024
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2024
CompletedFirst Submitted
Initial submission to the registry
March 4, 2024
CompletedFirst Posted
Study publicly available on registry
March 8, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2024
CompletedMarch 12, 2024
March 1, 2024
3 months
March 4, 2024
March 8, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Friction Index
Friction Index is used to assess temporomandibular function. The total scores range from 0 to 57, with higher scores indicating more severe temporomandibular dysfunction.
day 1 and day 15
Secondary Outcomes (3)
The Visual Analog Scale
day 1 and day 15
The maximum mouth opening limit
day 1 and day 15
Mann Assessment of Swallowing Ability
day 1 and day 15
Study Arms (2)
Routine rehabilitation treatment+Intra-articular Injection
EXPERIMENTALThe patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients in the experimental group are given routine rehabilitation treatment and intra-articular injections. Lidocaine is used as the injected medication at a dose of 2ml, administered once every 5 days for a total of three injections.
Routine rehabilitation treatment
ACTIVE COMPARATORThe patients receive a 15-day treatment and are required to stay in the hospital during this period. Patients are given routine rehabilitation treatment.
Interventions
Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint. Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance.
The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
Eligibility Criteria
You may qualify if:
- Presence of significant temporomandibular disorder clinical symptoms.
- Meeting the diagnostic criteria for Temporomandibular Joint Dysfunction and confirmed by X-ray examination.
- Patients voluntarily participate in this study and provide signed informed consent.
- Normal cognitive function
You may not qualify if:
- Rheumatic, rheumatoid, or other severe systemic diseases.
- Infectious temporomandibular joint arthritis or joint tumors.
- Individuals who have recently received joint injection treatment or photodynamic therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Muhammadlead
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Nieto Luis, Master
Site Coordinator of United Medical Group
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Research Director
Study Record Dates
First Submitted
March 4, 2024
First Posted
March 8, 2024
Study Start
March 1, 2024
Primary Completion
June 1, 2024
Study Completion
June 1, 2024
Last Updated
March 12, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share